Focal multimodality radiation therapy: A promising treatment for recalcitrant Darier disease

2018 ◽  
Vol 31 (4) ◽  
pp. e12641 ◽  
Author(s):  
Lina M. Rodriguez ◽  
Tiana Kazemi ◽  
Carol E. Cheng ◽  
Jung J. Kang ◽  
Phillip J. Beron ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Darier Disease ◽  
Promising Treatment

scholarly journals Radiation therapy for hepatocellular carcinoma: current status and perspectives from our experience

2011 ◽  
pp. 257-264
Author(s):  
Wei Jiang ◽  
Zhao-chong Zeng
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiation Therapy ◽  
Wide Spectrum ◽  
Distant Metastases ◽  
Current Status ◽  
Radiation Technology ◽  
Tumor Thrombosis ◽  
Liver Cancers ◽  
Advanced Stages ◽  
Promising Treatment

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and is accompanied by a poor prognosis. We had reported that radiation therapy has great potential, in a wide spectrum of primary liver cancers, fromlocal advanced stage of the disease to the more advanced stages, with regional nodal metastases, tumor thrombosis, and for palliation of distant metastases. Following the initial observation that HCC is radiosensitive and with the development of radiation technology, radiotherapy has become a feasible and promising treatment modality for HCC, particularly for advanced forms of the disease. Here, we review the substantial amount of available data on radiotherapy for HCC, report on the current status of this application of radiotherapy, and propose future avenues of research.

scholarly journals Radiation therapy for hepatocellular carcinoma: current status and perspectives from our experience

2011 ◽  
Vol 3 (4) ◽  
pp. 257
Author(s):  
Wei Jiang ◽  
Zhao-chong Zeng
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiation Therapy ◽  
Wide Spectrum ◽  
Distant Metastases ◽  
Current Status ◽  
Radiation Technology ◽  
Tumor Thrombosis ◽  
Liver Cancers ◽  
Advanced Stages ◽  
Promising Treatment

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and is accompanied by a poor prognosis. We had reported that radiation therapy has great potential, in a wide spectrum of primary liver cancers, fromlocal advanced stage of the disease to the more advanced stages, with regional nodal metastases, tumor thrombosis, and for palliation of distant metastases. Following the initial observation that HCC is radiosensitive and with the development of radiation technology, radiotherapy has become a feasible and promising treatment modality for HCC, particularly for advanced forms of the disease. Here, we review the substantial amount of available data on radiotherapy for HCC, report on the current status of this application of radiotherapy, and propose future avenues of research.

scholarly journals Intraoperative Radiation Therapy: A Promising Treatment Modality in Head and Neck Cancer

2017 ◽  
Vol 7 ◽  
Author(s):  
Lara Hilal ◽  
Karine A. Al Feghali ◽  
Paul Ramia ◽  
Ibrahim Abu Gheida ◽  
Jean-Pierre Obeid ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Treatment Modality ◽  
Intraoperative Radiation Therapy ◽  
Intraoperative Radiation ◽  
Promising Treatment

scholarly journals Immunotherapy Combined With Radiation Therapy for Genitourinary Malignancies

2021 ◽  
Vol 11 ◽  
Author(s):  
Jacob Ukleja ◽  
Erika Kusaka ◽  
David T. Miyamoto
Keyword(s):  
Radiation Therapy ◽  
Checkpoint Inhibitors ◽  
Dose Fractionation ◽  
Current Evidence ◽  
Early Clinical Trial ◽  
Promising Treatment ◽  
Enhance Tumor Cell ◽  
Clinical Trial Results ◽  
Tumor Cell Killing ◽  
Improve Treatment Efficacy

Immunotherapy drugs have recently been approved by the Food and Drug Administration for the treatment of several genitourinary malignancies, including bladder cancer, renal cancer, and prostate cancer. Preclinical data and early clinical trial results suggest that immune checkpoint inhibitors can act synergistically with radiation therapy to enhance tumor cell killing at local irradiated sites and in some cases at distant sites through an abscopal effect. Because radiation therapy is commonly used in the treatment of genitourinary malignancies, there is great interest in testing the combination of immunotherapy with radiation therapy in these cancers to further improve treatment efficacy. In this review, we discuss the current evidence and biological rationale for combining immunotherapy with radiation therapy, as well as emerging data from ongoing and planned clinical trials testing the efficacy and tolerability of this combination in the treatment of genitourinary malignancies. We also outline outstanding questions regarding sequencing, dose fractionation, and biomarkers that remain to be addressed for the optimal delivery of this promising treatment approach.

scholarly journals Darier disease, radiation therapy, and herpesvirus -- an unfortunate triad

2021 ◽  
Vol 27 (8) ◽  
Author(s):  
J Skylar Westerdahl ◽  
John Grant ◽  
Richard Sontheimer ◽  
Jamie Zussman
Keyword(s):  
Radiation Therapy ◽  
Darier Disease

scholarly journals Intra-arterial chemotherapy for retinoblastoma: a practical review

2013 ◽  
Vol 20 (4) ◽  
pp. 327-333 ◽  
Author(s):  
Jorge Balderrama ◽  
Carlos A. Leal-Leal ◽  
Hernando Alvis-Miranda ◽  
Angel Lee ◽  
Marco Zenteno ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Treatment Strategy ◽  
Injury Risk ◽  
Tumor Development ◽  
Therapeutic Tool ◽  
Tumor Extension ◽  
Secondary Tumor ◽  
Promising Treatment ◽  
Type Of Injury

Abstract The use of chemotherapy for retinoblastoma constitutes a promising treatment strategy. Retinoblastoma is the most common eye cancer in the childhood.. Treatment depends on the laterality, intraocular location and tumor extension. Radiation therapy became an important element in the management of this type of injury risk of extraocular secondary tumor development. Eye salvage is mandatory when vision preserved. The current neuroendovascular techniques constitute a therapeutic tool for these tumors. We present a practical review of current concepts in the management of these tumors.

scholarly journals Safety of Redo Hepatectomy for Colorectal Liver Metastases after Selective Interarterial Radiation Therapy: A Case Report

2014 ◽  
Vol 2014 ◽  
pp. 1-5
Author(s):  
Kyriakos Neofytou ◽  
Harpreet Wasan ◽  
Satvinder Mudan
Keyword(s):  
Radiation Therapy ◽  
Liver Resection ◽  
Liver Metastases ◽  
Colorectal Liver Metastases ◽  
Treatment Options ◽  
Right Hepatectomy ◽  
Number Of Patients ◽  
Promising Treatment ◽  
Sufficient Reduction ◽  
Lateral Sectionectomy

Surgical resection is the only potentially curative strategy in the treatment of patients with colorectal liver metastases (CLM). Unfortunately, only about 10%–15% of patients are candidates for resection. Preoperative chemotherapy aims to increase the number of patients that may be eligible for liver resection by downsizing liver metastases. For patients with unresectable, chemotherapy refractory CLM the available treatment options are limited. Selective interarterial radiation therapy (SIRT) is one of the most promising treatment options for this group of patients. Although only a small number of these patients have been reported as becoming candidates for potentially curative hepatic resection following sufficient reduction in the volume of liver metastases, the question arises regarding the safety of liver resection in these patients. We report a case of a patient who presented unresectable liver relapse of CLM after previous right hepatectomy. He underwent SIRT which resulted in downsizing of the liver metastases making the patient candidate for left lateral sectionectomy. He underwent the redo hepatectomy without any complications. To the best of our knowledge, this is the first reported case of redo hepatectomy after SIRT for CLM.

Sign in / Sign up

Export Citation Format

Share Document